Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I agree with you moneybox007.
Sure, there are some better performers on the IT lists, but they are sector driven - not global - so first you have to choose the right race, before choosing the horse.
With JGGI you are backing the stable.
Probably due to a) inflation stalling - prices are still +10% higher than they were in December 2022 but it's likely that 2) pay reviews have plugged some of the gap caused by inflation. However, as disposable income has been eroded to the point when nobody has any (by nobody, I mean 90% of the population - not those reading this LSE forum); what's the point of new clothing if you cannot afford to go out anywhere to spend it; which is why hospitality is still under the cosh.
As someone who has been invested in KWS for almost 5 years, I'm taken-aback by the fall in SP value in the past 6 months; it just makes no sense - but then the value of the company 6 months ago wasn't based on "now" but on future expectations. In year ending 31Dec2022, the company generated Eu68m profit on Eu691m t/o (approx 10%) and was valued at Eu2.45bn by the market. If you had Eu2.45bn jingling in your pocket, would you have bought KWS, or put the money into the banks paying 1.25%pa? KWS is a speculative investment, always has been - you are (in my opinion) hoping that the company develops a product (be it game, application, software etc) that is a "game changer". What is unfortunate, is that while the opportunity for that speculative breakthrough hasn't changed one jot, the recession background (war, inflation, food and energy shortages, nationalist governments) has forced the market to be more fundamental driven than speculative driven. On fundamental values, the SP could drop another 30% maybe even 50% to 760-800 because the turnover is just not good enough to justify the SP. It's a tough nut to crack - and much as I don't want to, I'm probably going to have to close my position completely. This is a great entry point for an optimist with a long time-frame; but that's not me unfortunately.
KWS has announced the appointment of Robert Kingston as its new chief financial officer from 1 July 2023.
The company added that Jon Hauck, its current chief financial officer, will assume the role of chief operating officer on 1 July, ensuring a smooth transition of responsibilities within the company's leadership structure.
Keywords noted that Kingston brings with him a wealth of experience in finance and operations within the technology and media sectors. His previous position was as CFO of Flutter Entertainment's UK and Ireland division, where he showcased his abilities in managing finance for acquisitive and internationally-focused companies. Prior to that, he held several senior finance and operational roles at Sky PLC over a span of 25 years, including finance director of Sky's Content Business and group director of Investor Relations.
And not a mention of anything from the BoD - are they all on holiday?
The SP is down 25% in May, and there appears to be no bottom to the fall-off developing. It looks likely that the SP will drop below 1952 that was touched in March 2022 - but for the life of me I've no idea why.
Why sell at 824?
Plenty of support following todays news on the acquisition. The future looks bright.
I really don't understand the relationship of todays results (which are good) and the SP
Up 8% yesterday, down 5% today - WTF is going on?
Prospects are looking positive - the SP has grown almost 10% since 1st Nov 22 (slow & steady); the discount is 13% and is reducing, historically it's usually about 5%.
15 months on from hitting an all-time-high of 3302 on 3rd Sept 2021, KWS hits a 12-month high of 3056 on 2nd Dec 2022.
In between, there's been plenty of ups and downs (1950 on 7th March 2022), but the recent trend has been up - as has been the trading figures. Fingers crossed that we see an SP of 4000+ in 2023.
It really doesn't make sense that this has reduced in market value by 30% in a week
Seems like I identified the low-point: the SP is up to 1289
A drop of 3% from yesterdays close of 1320p - currently (10:40am) the SP is at 1275.
No obvious reason as far as I know.
Anyone have any ideas?
I agree @devonplay: large discounts to NAV are not uncommon, they are the "norm". So when to sell is all about personal judgement, as you're most unlikely to obtain an SP close to NAV. I was hoping for 160+ but I'm likely to offload most of my holding for 145+ now - whenever that occurs next.
SkipJackTuna: this is what I posted on this BRH thread on 29Apr2021 (just before I sold out my stake and moved it into the company supplying the NHS with their covid-19 tests):
"the market has moved a long way since 1st March, that's what I'm trying to say.
What is the current testing policy in the UK? Any idea? Do you watch the news at all?
Every adult in the UK, every adult - that's about 50 million people - is entitled to TWO (2) FREE TESTS a week in the UK. These free tests started on 9th April, so (fair enough) I accept that on the 1st March nobody (except those in government) knew what was being planned.
So right now, some company, somewhere, is supplying the NHS will upto 100 million tests a week - this is happening right now, today (that company is Oxford Nanopore).
These free tests have been approved and are in the system, absolutely no doubt about that, none whatsoever.
If you are sat at home, does it matter a jot if the free test provided by the NHS gives you a result in 20mins or 10mins?
I think not.
The BRH test has no longer an NHS use option - that's gone, the bird has flown on that one.
The only option left is commercial use, and that market is limited.
We're talking flights, cruises, indoor stadia (sports events and theatre etc), conferences.
Compared to the free test market now dominated by the NHS (100 million tests a week), the UK commercial use market is probably less than a million tests a week, maybe a lot less."
LONDON (Reuters) -The initial public offering for Oxford Nanopore, a provider of rapid COVID-19 tests to Britain's national health services, will have an indicative price of 375 to 450 pence per share, a bookrunner said on Thursday.
The offer will total 523 million pounds ($713.16 million) to 547 million pounds, giving the life sciences company an implied market capitalisation of 3 billion to 3.5 billion pounds , the bookrunner said.